05:46 PM EDT, 10/07/2025 (MT Newswires) -- Legend Biotech ( LEGN ) said Tuesday its US unit entered into a new supply agreement with Janssen Pharmaceuticals to manufacture and supply ciltacabtagene autoleucel for clinical and commercial use worldwide, excluding Greater China.

The agreement, signed Monday, replaces an interim deal from February 2022 and covers production at the companies' Raritan, New Jersey, facility.

Janssen will pay Legend based on manufacturing costs plus a markup, with both companies sharing supply costs equally under their existing collaboration.